pembrolizumab,enfortumab vedotin
merck,astellas,seagen
['ev-103', ' ev ', 'pembro']
ev-103 cohort k: encouraging activity with ev and pembro pfs not reached with, 65% orr, mos 22.3 months regardless of nectin-4 #esmo22 
Pursuing to improve cancer prevention and care. Medical Oncologist @AnkaraUni